Charlotte’s Web Sponsoring Research To Address FDA’s Request For More Scientific Data
Charlotte’s Web, one of The CBD Insider’s trusted brands, announced this week that it had joined six other CBD brands to sponsor a study that will address the Food and Drug Administration’s (FDA) request for more scientific data from the CBD industry.
Conducted by third-party research platform, ValidCare, which provides data to improve research and regulations in the hemp and healthcare industries, the human trial study will determine if the daily use of full-spectrum, hemp-derived CBD impacts liver function. The study, set to deploy next month, is in response to the FDA’s public comments to Congress on March 5, 2020.
More than 100 CBD companies were invited to take part in the study, but Charlotte’s Web is one of only seven to agree to participate. CBDistillery, another trusted brand of The CBD Insider, is also involved.
“As the market share leader, anchored in science, sponsoring ValidCare’s study made strategic sense for us,” said Deanie Elsner, Chief Executive Officer for Charlotte’s Web. “This research will provide important clinical data to guide our entire industry while also showing the FDA we’ve heard their requests and are answering their questions with precise data.”
Vice President of Innovation for Charlotte’s Web, Tim Orr, added, “This is a particularly important time for research on the science behind hemp-derived CBD as we advocate for FDA regulation of our category. Charlotte’s Web invests in scientific research, including internal and external independent studies such as ValidCare’s. Prioritizing the science is essential to ensuring product safety, effectiveness and consumer trust.”
The study, originally slated for March but pushed back due to the COVID-19 pandemic, will gather data from roughly 1,000 people from July through September.
NBA Hall Of Famer Isiah Thomas Appointed CEO Of One World Pharma
One World Pharma announced this week that it has named NBA Hall of Famer, Isiah Thomas, as CEO.
In addition to CEO, Thomas will also serve as vice-chair of the company’s board of directors. Thomas replaces the retiring One World Pharma founder, Craig Ellins, as CEO.
One World Pharma is a CBD company in Las Vegas that grows its hemp and marijuana on a 30-acre cultivation facility in Popayan, Colombia. The company claims to have spent more than two years developing relationships with farmers and provides education to help develop genetics.
Thomas, a 12-time NBA All-Star and two-time NBA champion, played 13 seasons for the Detroit Pistons. He was recently in the news as his snub from the 1992 Dream Team was brought back into the spotlight during The Last Dance, a documentary series on ESPN chronicling Michael Jordan’s last season with the Chicago Bulls.
In his post-playing career, Thomas has emerged as a savvy businessman, with a portfolio that includes the Toronto Raptors, Popcorn Indiana, Cherlin Champagnes, and CBD company, VESL Oils.
“We are elated to welcome Isiah Thomas to the One World Pharma leadership team and to have him continue and expand upon the successes of Craig Ellins,” stated Dr. Kenneth Perego, Executive Chairman of One World Pharma. “Mr. Thomas is the ideal person to lead us in this new phase as we commence commercial sales and revenues, lending to our cause his international business experience, myriad relationships, and commitment to winning.”
“I am honored to join One World Pharma and its excellent team,” said Thomas. “It is a company that is leading the way in innovation in the hemp and cannabis industry. The company’s deep commitment to excellence in their products and for its customers positions us well to continue to grow as an international leader in the industry. Its recognition for its humanitarian efforts validates its mission as a socially conscious company in a true partnership with the indigenous people.”